News
Video
Author(s):
Dr. Nader Sanai presents the findings of a phase 0/1 trigger trial (NCT06072586) that evaluates the CNS penetration of BDTX-1535 in patients with recurrent high-grade gliomas and EGFR mutations.
Vorasidenib Breaks Through as the First Systemic Therapy for Select Patients With Glioma
Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma
FDA Grants Orphan Drug Designation to Opaganib for Neuroblastoma
INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma
Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
Dr Seymour on the Role of Mutational Profiling in CLL
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL